Why carry out this study?

There is no clear consensus on the order of preference for biologics in psoriasis.

Appropriate selection of the next therapeutic agent following discontinuation of a drug due to ineffectiveness or adverse events is particularly challenging.

We examined drug survival of the subsequent biologics selected for patients with psoriasis who had discontinued TNF inhibitors to determine which drugs were more likely to be continued.

What was learned from the study?

Among patients who discontinued TNF inhibitors due to inadequate efficacy, female sex was a predictor of drug discontinuation and taking interleukin-17 inhibitors rather than TNF inhibitors was a predictor of drug continuation.

Interleukin-17 inhibitors may be a favorable option for patients who discontinue TNF inhibitors due to inadequate efficacy and need to switch to other agents.